跳至主要内容
临床试验/NCT06869252
NCT06869252招募中1 期

Autologous Adipose Cells Therapy

CERM INC.2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
40
试验地点
2
主要终点
Visit Evaluation Report

研究概览

简要总结

Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.

详细描述

Autologous fat grafting (AFG) and injection of dermal fillers are the most prevailing aesthetic procedures in the cosmetic field for skin rejuvenation and hair restoration. High degree of biocompatibility and biodegradability of dermal fillers contribute significantly to their effectiveness in skin rejuvenation and hair restoration; however, the results are typically not enduring. On the other hand, autologous fat grafting is increasingly recognized for its applications not only in skin rejuvenation, but also breast augmentation and the treatment of arthritis. Fat fillers are fully biocompatible to the recipient, due to the use of autologous cell, the effects generally persist longer than those achieved with dermal fillers. Nonetheless, unprocessed lipoaspirate collected through liposuction procedure has a heterogeneous composition, which potentially leads to uneven distribution of adipose tissu resulting in formation of lumps or nodules at the recipient's site. Volume retention following autologous fat grafting is not solely affected by the resorption rate of adipose cells, but also impacted by re-uptake rate of other components of lipoaspirate. Autologous Adipose Cell Therapy seeks to enhance the current autologous fat grafting by isolating early-stage adipose cells from lipoaspirate and optimizing the number of adipocytes cells within the fat filler through cell property of differentiation. The purpose of this study is to assess the safety, feasibility, and efficacy of Autologous Adipose Cell Therapy for skin rejuvenation and hair improvement in human subjects. The eligibility of participants who are interested in participating in this study will be determined based on the inclusion and exclusion criteria listed in the study protocol. The in-charge plastic surgeon will monitor and evaluate the treatment outcomes in participants over a six-months period after the administration of Autologous Adipose Cell Therapy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.
  • •Outpatients who are experiencing hair loss or hair thinning
  • •Provision of signed and dated informed consent form
  • •Clearly stated willingness to comply with all the procedures of the study and availability of the study
  • •Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor

排除标准

  • •Pregnancy or lactation
  • •Known allergic reaction to components of cell culture media
  • •Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures
  • •Chronic infections, e.g. skin fungi infection, psoriasis
  • •Chronic wound healing
  • •Currently taking hormone therapy
  • •History of cancers and active cancers
  • •Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.

研究组 & 干预措施

Autologous Adipose Cells Therapy

Experimental

干预措施: Autologous Adipose Cells Therapy (Biological)

结局指标

主要结局

Visit Evaluation Report

时间窗: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

During each post-treatment visit, the responsible plastic surgeon will assess the treatment outcomes and evaluate the degree of improvement by comparing the pre-treatment image with the current post-treatment image. Scale of Improvement: * No Improvement(0%) * Minimal Improvement(1% - 25%) * Moderate Improvement(26% - 50%) * Significant Improvement(51% - 75%) * Major Improvement(76% - 100%) Assessment Parameters: Skin: * Radiance * Texture * Firmness * Wrinkles \& Fine Lines * Spot Hyperpigmentation * Tone * Redness \& Inflammation * Pore Size Hair: * Density * Thickness * Visual Appearance * Texture (Smoothness \& Frizz Control) * Shine * Scalp Health

Outcome Comparison Survey

时间窗: The end of the study (Week 20 to 25)

30 people will be randomly selected to rank the level of improvement by comparing the images captured at pro and post-treatment from Imaging assessment. Scale of Improvement: * No Improvement(0%) * Minimal Improvement(1% - 25%) * Moderate Improvement(26% - 50%) * Significant Improvement(51% - 75%) * Major Improvement(76% - 100%)

Participant Satisfaction Survey

时间窗: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

Participants will be requested to complete a list of questions related to their experience and satisfaction of autologous adipose cell therapy in each study visit for result evaluation. 1-to-5 Scales: * 1 being "very poor" and 5 being "excellent" * 1 being "very dissatisfied" and 5 being "very satisfied"

Imaging Assessment

时间窗: From first pre-treatment visit to the last follow-up visit at week 16 to week 25

Digital images of the target site will be captured for each participant both prior to and following autologous adipose cell therapy for the purpose of outcome evaluation. The comparison of pre- and post-treatment images will be utilized in the "Outcome Comparison Survey" and the "Visit Evaluation Report" to assess the degree of improvement, based on the established assessment parameters for Autologous Adipose Cell Therapy treatment.

Case Report Form

时间窗: The report will be completed at the end of the study (Week 20 to 25), but highlights would be recorded in this document during every visit.

A comprehensive medical document will be prepared by the responsible plastic surgeon which outlines the key details of each stage of the treatment process and aspects based on each participant's case. This document will include a thorough description of the patient's presenting medical conditions, the surgical procedures performed, post-treatment progress, any adverse events that occurred, and the final outcomes.

次要结局

未报告次要终点

研究者

发起方
CERM INC.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验